Pharma Business review -

Pharma Business review is using cookies

Continue Learn More

Close

September 24, 2018

Novartis plans to file for new Lucentis indication in ROP

Novartis has unveiled plans to file ex-US for a new indication for Lucentis (ranibizumab) in retinopathy of prematurity (ROP), a rare disease in premature infants.

Image: Novartis headquarters in Basel, Switzerland. Photo: courtesy of Novartis AG.

September 21, 2018

Mylan, Fujifilm Kyowa get EC nod for Humira biosimilar Hulio

Image: Head office of the European Commission. Photo: courtesy of Amio Cajander.

September 20, 2018

OBI Pharma’s OBI-3424 gets FDA orphan drug status to treat ALL

Image: FDA grants orphan drug designation to OBI Pharma’s OBI-3424 for the treatment of ALL. Photo: courtesy of The U.S. Food and Drug Administration/Wikipedia.org.

Contracts

September 21, 2018

Opiant signs contract with BARDA to accelerate OPTN003 product development

Image: Opiant Pharmaceuticals has signed contract with BARDA to accelerate development of nasal nalmefene to treat opioid overdose. Photo: courtesy of Baitong333 / FreeDigitalPhotos.net.

BioCryst bags contract to supply RAPIVAB antiviral flu therapy doses to CDC

Drug Manufacturing

Data science company IXICO extends contract with biopharmaceutical firm

Abzena signs manufacturing and bioconjugation deal with Telix

Deals

Deals September 20, 2018

Grifols secures FTC’s conditional approval for Biotest US acquisition

Pharmaceutical Business Review

Allergan to buy clinical-stage biotechnology firm Bonti for $195m

Boehringer Ingelheim buys Austrian firm ViraTherapeutics for €210m

Carlyle buys minority stake in US CDMO Ambio from MVM Partners

Popular

Videos

Suppliers

Spotlight

Pharmaceutical Business Review

Novo Nordisk to slash 400 jobs in R&D restructuring

Pharmaceutical Business Review

ACCC clears merger of generic pharmaceutical firms Arrow and Apotex

Pharmaceutical Business Review

Boehringer Ingelheim buys Austrian firm ViraTherapeutics for €210m